Alice T. Shaw, MD, PhD

Articles

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

August 2nd 2019

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Dr. Shaw Discusses Lorlatinib in Lung Cancer

May 3rd 2018

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses lorlatinib in the treatment of patients with lung cancer.

Dr. Shaw Discusses Efficacy of Lorlatinib in ALK+ NSCLC

April 18th 2018

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the efficacy of lorlatinib in ALK-positive non–small cell lung cancer.

Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC

June 6th 2017

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the phase III results of the international ALEX trial, which compared the alectinib (Alecensa) with crizotinib (Xalkori) in the frontline setting for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer

January 18th 2017

Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib as first-line therapy in the treatment of patients with lung cancer.

Dr. Alice T. Shaw on Ceritinib for Frontline ALK+ NSCLC With Brain Metastases

November 4th 2016

Alice T. Shaw, MD, PhD, thoracic oncologist at the Massachusetts General Hospital Cancer Center, discusses ceritinib in newly diagnosed patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases.

Dr. Shaw on Overcoming Resistance in Lung Cancer

April 23rd 2015

Alice Tsang Shaw, MD, PhD, thoracic oncologist, Massachusetts General Hospital Cancer Center, discusses overcoming resistance to targeted therapy in lung cancer.

Dr. Shaw on LDK378 and Alectinib for ALK+ NSCLC

February 10th 2014

Alice T. Shaw, MD, PhD, discusses the two most advanced next-generation ALK-inhibitors for the treatment of non-small cell lung cancer (NSCLC): LDK378 and alectinib (AF802).

Dr. Shaw on Crizotinib as a Standard of Care in NSCLC

January 9th 2014

Alice T. Shaw, MD, PhD, discusses how crizotinib has changed patient care over the last few years.

Dr. Shaw on Monitoring Crizotinib-Related Side Effects

November 10th 2013

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses monitoring adverse events associated with crizotinib when treating patients with ALK-positive lung cancer

Dr. Shaw Compares Crizotinib and Chemotherapy in NSCLC

July 19th 2013

Lead author, Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital, reviews the first published results from a randomized phase III trial investigating crizotinib in patients with ALK-positive non-small cell lung cancer.

Dr. Shaw Describes LDK378 in ALK-Positive Lung Cancer

June 5th 2013

Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, discusses the clinical activity of the ALK inhibitor LDK378 in patients with non-small cell lung cancer harboring an ALK alteration.